FDA Calls for More Data on Dupilumab for CSU Indication

In a letter, the FDA stated that additional efficacy data are required to support an approval for chronic spontaneous urticaria (CSU), according to the manufacturers of dupilumab.

Related Keywords

Berlin ,Germany ,United States ,American ,Omalizumab Xolair ,Dupilumab Dupixent ,Drug Administration ,American Academy Of Allergy ,European Academy Of Dermatology ,European Academy ,Urticaria ,Angioedema ,Lives ,Biologic Therapy ,Antihistamine ,Pruritus ,Pruritis ,Pitch ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Asthma ,Sthmatic ,Anti Immunoglobulin E ,Nti Ige ,Allergy ,Clinical Research ,Clinical Trials ,Linical Studies ,Europe ,European ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,The ,